Genomma Lab Internacional SAB de CVBMV: LAB/B

LAB/B: Exceptional 2024 results: strong sales, record profits, margin expansion, and robust cash flow

· Issued by Genomma Lab Internacional SAB de CV

Q4 and full year 2024 saw double-digit sales and profit growth, with EBITDA and net income surging, margins expanding, and record free cash flow. Growth initiatives and reinvestment of productivity gains are set to accelerate future performance, with stable dividends and low leverage maintained.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Genomma Lab Internacional SAB de CV on 6ix

Earlier from Genomma Lab Internacional SAB de CV

Later from Genomma Lab Internacional SAB de CV

All Genomma Lab Internacional SAB de CV news releases